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Hematopoietic stem/progenitor cells (HSPCs) are
capable of supporting the lifelong production of
blood cells exerting a wide spectrum of functions.
Lentiviral vector HSPC gene therapy generates a hu-
man hematopoietic system stably marked at the
clonal level by vector integration sites (ISs). Using IS
analysis, we longitudinally tracked >89,000 clones
from 15 distinct bone marrow and peripheral blood
lineages purified up to 4 years after transplant
in four Wiskott-Aldrich syndrome patients treated
with HSPC gene therapy. We measured at the clonal
level repopulating waves, populations’ sizes and dy-
namics, activity of distinct HSPC subtypes, contribu-
tion of variousprogenitor classes during the early and
late post-transplant phases, and hierarchical rela-
tionships among lineages. We discovered that in-
vitro-manipulated HSPCs retain the ability to return
to latency after transplant and can be physiologi-
cally reactivated, sustaining a stable hematopoietic
output. This study constitutes in vivo comprehensive
tracking in humans of hematopoietic clonal dynamics
during the early and late post-transplant phases.
INTRODUCTION
The hematopoietic system is a complex hierarchical structure that
produces several different types of specialized blood cells, most
ofwhich are short-lived and thereby require continuous replenish-
ment with hematopoietic stem/progenitor cells (HSPCs). Autolo-
gous or allogeneic transplantation of HSPCs is widely used toCell Stem Cell 19, 107–119
This is an open access article under the CC BY-Nreconstitute functional hematopoiesis in patientswith hematolog-
ical diseases (Cavazzana-Calvo et al., 2013; Gschweng et al.,
2014; Jenq and van den Brink, 2010; Mohty et al., 2014; Naldini,
2011; Williams, 2013). Despite the well-established clinical use
of HSPCs, their short- and long-term fate after transplantation
and the clonal dynamics of hematopoietic reconstitution in hu-
mans remain poorly understood. Over the past few years, a series
of phenotypic and functional characterization studies have identi-
fied various HSPC subpopulations within cells expressing the
CD34 antigen, including hematopoietic stem cells (HSCs), which
are the most undifferentiated stem cell type, and multipotent pro-
genitors (MPPs), which are downstreamof the differentiation hier-
archy but still capable of multilineage output (Doulatov et al.,
2012). Different cell hierarchies of human hematopoiesis have
been proposed, including the early branching of myeloid and
lymphoid lineages (Akashi et al., 2000; Kondo et al., 1997) or the
ontological proximity of lymphoid lineages to myeloid compart-
mentsdue to the existenceof amyeloid-primed lymphoid progen-
itor that is distinct from HSC (Ema et al., 2014; Kawamoto et al.,
2010a).DataonHSPCactivity havebeencollectedmainly through
in vitro assays or using humanized, wild-type animal models (Ba-
bovic and Eaves, 2014; Benveniste et al., 2010; Cheung et al.,
2013;Nolta et al., 1996;Notta et al., 2011;Wright et al., 2001). Bar-
coded vector libraries and retroviral integration sites (ISs) have
been used to track HSPCs upon transplantation in small animal
models and in non-human primates (Dykstra and Bystrykh,
2014; Gerrits et al., 2010; Kim et al., 2014; Naik et al., 2013; Perie´
et al., 2014; Wu et al., 2014). Additionally, recent mouse studies
marking HSPCs in vivo suggest that unperturbed hematopoiesis
may be driven more substantially by MPPs rather than by HSCs
(Sun et al., 2014). Ideally, hematopoietic clonal dynamics should
be studied by tracking the fate of individual clones in humans,
revealing the rate and extent of hematopoietic recovery after
transplant, and evaluating the possibility of long-term exhaustion
due to in vitro cell manipulation. Such a study would have highly, July 7, 2016 ª 2016 The Author(s). Published by Elsevier Inc. 107
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1. Total Number of Unique Integration Sites and Relative
Sequence Reads Retrieved from Four WAS Patients up to 48
Months after GT
Patient Number of ISs Sequence Reads
Patient 1 27,489 5,773,290
Patient 2 25,535 9,405,296
Patient 3 24,779 6,539,976
Patient 4 11,791 6,882,455
Total 89,594 28,601,017
Table 2. Cumulative Number of Unique Integration Sites
Retrieved on the Infused Cell Product and at Different Time
Points after GT from Different Cell Types Purified from the BM or
PB of 4 WAS Patients
Samples Patient 1 Patient 2 Patient 3 Patient 4
Pre-infusion 1,228 938 619 622
BM CD34 1,277 2,542 2,357 1,409
BM CD14 1,205 778 2,925 2,481
BM CD15 3,233 4,056 4,135 2,840
BM CD19 2,332 5,158 5,083 2,084
BM CD3 3,650 3,707 5,999 1,536
BM CD56 1,217 3,335 3,849 1,746
BM CD61 1,140 735 1,721 1,642
BM GLYCO 1,194 1,863 2,633 1,337
PB CD14 8,691 5,881 7,402 2,764
PB CD15 7,391 7,084 6,007 2,314
PB CD19 8,804 8,558 11,351 3,358
PB CD3 6,874 5,886 6,323 2,908
PB CD4 10,839 7,490 6,993 2,798
PB CD8 5,975 4,017 4,409 2,256
PB CD56 6,953 7,977 3,203 2,194
GLYCO, glycophorin+ cells.relevant implications for the broad clinical use of HSPCs and the
long-term prognosis of treated patients.
Ex vivo gene therapy (GT), based on the permanent gene
correction of human HSPCs through the transfer of a therapeutic
gene using retroviral (RV) or lentiviral (LV) vectors, has recently
provided preliminary evidence of safety and efficacy for the
treatment of various blood-borne genetic disorders (Aiuti et al.,
2009, 2013; Biffi et al., 2013; Candotti et al., 2012; Gaspar
et al., 2011; Hacein-Bey Abina et al., 2015; Hacein-Bey-Abina
et al., 2010; Naldini, 2011, 2015; Williams, 2013). Following GT,
each vector-marked cell is univocally barcoded by a vector IS,
providing an ideal setting for the study of human hematopoiesis
(Naldini, 2015). We and others have already shown that IS-based
tracking can be exploited to study the clonal composition of en-
gineered cells and to assess the safety of gene transfer as well as
the in vivo engraftment of markedHSPCs (Aiuti et al., 2007, 2013;
Biasco et al., 2015; Hacein-Bey Abina et al., 2015; Tey and Bren-
ner, 2007; Wang et al., 2010).
In the present study, we used IS-based clonal tracking on indi-
vidually purified lineages to examine early and late human hema-
topoiesis up to 4 years after transplant in the context of LV GT for
Wiskott-Aldrich syndrome (WAS), an inherited disorder charac-
terized by thrombocytopenia, bleeding episodes, eczema, and
immunodeficiency (Aiuti et al., 2013).Wemeasured, at qualitative
and quantitative levels, the contribution of progenitors to an
extensively engineered hematopoietic system and assessed
over time the in vivo clonal relationships among blood cells,
providing crucial information on humanhematopoietic dynamics.
RESULTS
Tracking of Clonal Dynamics and Estimates of
Population Size of Engineered Cells
During a 3- to 4-year follow-up period, we studied the clonal dy-
namics and relationships of gene-corrected cells in fourWASpa-
tients treated with LV HSPC GT (Aiuti et al., 2013; Castiello et al.,
2015). The patients received an average cell dose of 10.8 million
CD34+ cells/kg, with gene-correction efficiency ranging from
88% to 100%. All patients were alive and well after GT, with no
reports of eczema or major bleeding episodes. Patients showed
multilineage reconstitution of engineered cells, and no sign of se-
vere adverse events related to treatment (Aiuti et al., 2013; Cas-
tiello et al., 2015).
We collected IS from eight distinct peripheral blood (PB)
and seven distinct bone marrow (BM) lineages, as well as from
whole PB, whole BM, and mononuclear cell samples using a
combination of linear-amplification-mediated (LAM)-PCR and108 Cell Stem Cell 19, 107–119, July 7, 2016next-generation sequencing (NGS) technologies. This yielded
28,601,017 sequence reads, which were mapped to 89,594 indi-
vidual ISs (Tables1and2). Eachclonewasunivocally identifiedby
its integration locus and nearest gene. Sequence reads belonging
to each IS were used as surrogate markers of relative clonal size.
We first estimated the evolution of the clonal repertoire of
gene-corrected cells over time by calculating the diversity index
for each sample and time point on the basis of richness (number
of unique ISs marking individual clones) and evenness (relative
clonal contribution in terms of sequence reads associated to
each IS). The diversity index of pre-infusion samples was consis-
tent among patients, ranging between 5.6 and 6.2 (Figure 1A),
and represented the highest average level of polyclonality
observed, as expected from a heterogeneous population con-
taining a large number of committed non-engrafting progenitors.
After intravenous infusion in patients, we found that the diversity
of the clonal repertoire of genetically engineered PB cells was
lower in the early phases of hematopoietic reconstitution.
It then stabilized in all patients after the first 6–9 months and
remained steady until the last follow-up at 4 years after GT
(diversity index ranging from 3.6 to 5.9; Figure 1A). In particular,
when analyzing individual lineages, including BM samples,
we observed fluctuation of the diversity index during the first
3months after GT (Figures 1B and S1). Lymphoid cells displayed
lower diversity in the early months after GT compared to myeloid
lineages, in concordance with previously observed delayed
lymphoid reconstitution (Aiuti et al., 2013). Conversely, myeloid
cells better mirror the early clonal dynamics of BM CD34+ pro-
genitors when compared to B and T lymphocytes (Figure S1).
Since the differences in diversity might be affected by an
uneven collection of ISs over time, we compared diversity on
randomized subsamples of identical amounts of ISs, confirming
that in both myeloid and lymphoid lineages, the highest diversity
Figure 1. Tracking of Engineered Popula-
tion Dynamics and Clonal Abundance over
Time
(A) Diversity index calculated on number of ISs and
relative sequence counts of pooled PB lineages
purified from four patients over time. Black asterisk
on the y axis indicates the average diversity index
of pre-infusion samples.
(B) Diversity index of BM CD34+ cells (in red) and
individual samples over time (in gray) from a
representative patient (patient 2). Red asterisk
shows the diversity index of BM CD34+ cells
before infusion.
(C) Estimates of population clonal abundance of
PB mature lineages from four WAS patients. Time
intervals are reported as months after GT on the x
axis of each graph.
(D) Overall clonal size estimates of BM CD34+ and
PB mature populations at the last follow-up when
both BM and PB were collected (36 months after
GT for patients 1, 2, and 3 and 24 months for
patient 4). FU, follow-up.
See also Figures S1 and S2.in vivo was observed at the last time points, irrespective of the IS
sample size (Supplemental Experimental Procedures). To eval-
uate whether clonal relationships among lineages and time
points also changed over time, we calculated pairwise positive
associations on the basis of the sharing of identical ISs between
two cell types (Supplemental Experimental Procedures). Using
unsupervised clustering, we distinguished two major phases
of hematopoietic reconstitution. The most stable sharing of
identical ISs was observed over a period ranging from 3–6 to
48months post-GT (Figure S2). This outcomewas not influenced
by potential background detection of IS contaminants associ-
ated with a low number of sequence reads, as these results
were confirmed even after stringent data filtering to progres-
sively remove poorly represented ISs from the datasets (Supple-
mental Experimental Procedures).
Although population size estimates have been performed
inanimalclonal trackingstudies (Kimetal., 2014), there iscurrently
no information available on the number of clones that makeCeup different cell compartments derived
from transplanted HSPCs in humans in
steady-state hematopoiesis. In order to
comprehensively address this point, we
first calculated the probability of recaptur-
ing identical ISs within the same lineages
over time.Weobserved a general increase
in the probability of recapturing identical
clones over time, which reached a stable
level at 12 months after GT (Supple-
mental Experimental Procedures).
On the basis of these results, we
then estimated, using Markov processes
enclosed on an open population esti-
mator, the number of clones making up
different PB lineages isolated after
12 months (Supplemental Experimental
Procedures). As shown in Figure 1C, theestimated population size of differentiated PB gene-corrected
clones was constant over a period of 2–3 years in all patients,
ranging between 1,600 and 4,300 clones. The estimated total
number of clones differed between lineages and was greater in
the lymphoid compartment than in the myeloid one (Figure 1D).
This result is consistent with the longer survival potential of
lymphoid cells and with the early effects of selective advantage
for gene-corrected lymphocytes expressing WAS protein (Aiuti
et al., 2013; Scaramuzza et al., 2012). Within the BM CD34+
cell population, the number of clones was higher in the early
post-GT phase and decreased over the following months to a
smaller steady-state population composed of 1,200 clones
(Supplemental Experimental Procedures).
Longitudinal Analysis of HSPC Activity in the Early and
Late Phases of Hematopoietic Reconstitution
In order to study the clonal output of transduced progenitors to
differentiated lineages, we evaluated the level of IS sharingll Stem Cell 19, 107–119, July 7, 2016 109
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Figure 2. IS Sharing and Clonal Output of BM CD34+ Progenitors over Time
(A) Bar charts showing the percentage of IS from BMCD34+ cells shared with only myeloid (green), only lymphoid (blue), and both myeloid and lymphoid lineages
(orange) from the same time point (months after GT). The fractions of ISs detected only in BM CD34+ cells at each given time are shown in gray. Data have been
filtered for potential cross-contaminations as described in Supplemental Experimental Procedures.
(B) Circos plots showing the levels of CD34+ output measured as multilineage sharing of ISs from BMCD34+ cells over time (ordered in columns per months after
GT). The rainbow area of the circle is composed of ribbons showing relative IS sharing toward different BM and PB lineages listed on the left. The red area
comprises the total number of IS from CD34+ cells. The larger the rainbow area compared to the red area, the higher the CD34+ output. The more colored the
rainbow area, the more diverse and multilineage the CD34+ output.
(legend continued on next page)
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between BM CD34+ and myeloid or lymphoid cells over time. As
shown in Figure 2A, the percentage of ISs shared between
CD34+ cells and myeloid or lymphoid lineages was much lower
in early versus late time points, the lowest being at 3months after
GT. The nature of the output measured at later time points was
predominantly bi-potent (myeloid and lymphoid), reflecting the
activity of multipotent progenitors. Althoughwe applied stringent
filters before performing this analysis to account for potential
cross-contamination, a similar trend was observed even when
analyzing the entire dataset (Supplemental Experimental Proce-
dures). This suggests that the observed increase in shared inte-
grations reflects an underlying biological phenomenon and is not
simply due to technical artifacts of potential contamination
among purified subpopulations, which would not be expected
to change owing to the time of collection.
We then expanded the analysis of CD34+ cell output to all lin-
eages isolated from the BM and PB of WAS patients over time.
The ‘‘rainbow’’ area of the plots in Figure 2B shows the IS per-
centage shared between BM CD34+ cells and each of the puri-
fied cell subtypes. During the first 3 months, we observed a
shrinkage in output toward all lineages analyzed for each patient.
Starting at 6 months, the level of IS sharing increased, and pro-
genitor output was highly distributed to all lineages. This sub-
stantial multipotent output was consistently maintained up to 3
years after GT.
To formally validate IS sharing as being representative of
progenitor activity, we isolated ISs from colony-forming cells
(CFCs) generated in vitro from the same CD34+ cells analyzed
above at the last follow-up when patient hematopoiesis was
steady state. These represented highly purified samples, in
which at the end of clonogenic assay, contamination with
mature cells from the original harvest was virtually absent. The
average vector copy number (VCN) of vector-positive CFCs,
at the latest follow-up available, ranged from 1.2 to 1.7. As
shown in Table S1, we observed a substantial percentage of
IS retrieved from CFCs in each patient analyzed, identical to
those detected in myeloid and/or lymphoid cells isolated in vivo
at the same time point.
To gain additional information on HSPC activity, we then
studied the datasets from the opposite perspective, evaluating
the input level that each lineage received from CD34+ cells at
different time points. Figure 2C shows on a heatmap the pro-
portion of ISs within each lineage and time point shared with
CD34+ progenitors over time. In line with the data reported
above, the greatest IS similarities between different cell types
and BM CD34+ cells were observed at the last follow-up after
GT. Unsupervised clustering for lineages and sources showed
that PB lymphoid cells, myeloid cells, and megakaryocte-
erythroid progenitors clustered separately from each other on
the basis of their relationships with BM CD34+ precursors.
CD56+ natural killer (NK) cells isolated from BM or PB were
found to be co-clustered with myeloid cells purified from PB
and not with lymphoid T cells that were rather grouped
independently.(C) Heatmap using blue-to-green color intensity to show the frequency of IS sha
a measurement of clonal input received with BM CD34+ progenitors. Unsuper
Procedures.
See also Table S1 and Supplemental Experimental Procedures.Assessment of HSC and MPP Contribution to
Engineered Hematopoiesis over Time
Previous studies using xenotransplantation assays have identi-
fied the human Lin/CD34+/CD38/CD90+/CD45RA fraction
as being endowed with long-term repopulation potential (Doula-
tov et al., 2012; Laurenti and Dick, 2012; Laurenti et al., 2013;
Majeti et al., 2007). Recent studies on mice have questioned,
however, whether HSCs and/or MPPs are responsible for the
steady-state maintenance of blood cell production in humans
(Sun et al., 2014). To address this point, we used fluorescence-
activated cell sorting (FACS)-sorted HSC (defined as Lin/
CD34+/CD38/CD90+/CD45RA) and MPP (defined as Lin/
CD34+/CD38/CD90/CD45RA) progenitor subpopulations
from CD34+ cells isolated from the BM of two WAS patients at
36 months after GT, and we collected ISs from each subtype
(Supplemental Experimental Procedures). Using IS analysis,
we backtracked the activity of 51 HSC and 10 MPP genetically
engineered clones in the two patients. The heatmap in Figure 3A,
at 36months after GT, shows that 15 out of 51 and 8 out of 10 ISs
isolated from HSCs or MPPs, respectively, were detected in at
least one other lineage and time point. The majority of ISs
collected from HSCs and MPPs could be traced back over
multiple lineages isolated at different time points, but their
activity appeared more consistent after the first 3–6 months
following GT.
To evaluate the real-time output of these clones on the BMand
PB of WAS patients, we quantified the contribution in terms of
the sequence reads of these IS on whole BM, whole PB, and
mononuclear cell samples collected at 36 months after GT (Fig-
ure 3B). In line with their predicted biological behavior from xen-
otransplantation studies, only a fraction of the HSCs appeared to
be actively contributing to the hematopoietic output at the time
of sampling, while almost all MPPs were doing so. Nonetheless,
HSC clones displayed a higher contribution to the PB and BM
samples of the same time point compared to MPP clones. We
also quantified the output of HSCs andMPPs over all time points
by calculating ‘‘sharing scores,’’ i.e., the level of identical ISs
detected in HSCs or MPPs and various myeloid and lymphoid
lineages over time (Supplemental Experimental Procedures).
As a result, we found that both HSC and MPP clones isolated
at 36 months after GT had actively participated in myeloid and
lymphoid production for a period of 2.5 years, starting from
3 to 6 months after infusion of gene-corrected CD34+ cells
(Figure 3C).
Analysis of Clonal Relationship among Individual
Lineages in Steady-State Hematopoiesis
The level of detail achieved by our IS-based clonal trackingmight
allow assessment of the hierarchical relationships among engi-
neered blood cell types in humans. To test the validity of different
models of hematopoietic hierarchy, we first evaluated the overall
biological consistency of four different parameters of molecular
tracking in steady-state hematopoiesis (Figure 4A). The per-
centage of shared integrations was higher in BM CD34+ cells,red by each lineage (in rows) with BM CD34+ cells (in columns) over time as
vised clustering was performed as described in Supplemental Experimental
Cell Stem Cell 19, 107–119, July 7, 2016 111
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Figure 3. Analysis of Purified HSC and MPP Output over Time
(A) Output of HSC and MPP progenitors over time isolated from patient 2 (Pt2) and Pt3 at 36 months after GT. Bar graphs on the left show the fraction of HSC or
MPP ISs (in blue) detected in multiple lineages and time points. Heatmaps on the right show the detection of each shared IS (in rows) over time. Each column
represents an individual lineage and time point. Blue color intensity is proportional to the level of multilineage and over-time detection of each shared IS. The
number of clones (15 HSCs and 8 MPPs) mentioned in the text is the sum of the clones identified as sharing ISs with at least one other lineage in the two patients
over time (HSC clones: 6 (heatmap above) + 9 (heatmap below) = 15; MPP clones: 4 (heatmap above) + 4 (heatmap below) = 8).
(legend continued on next page)
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consistent with the hierarchical level of these precursors
compared to other subtypes, while it was lower in the lymphoid
compartment. Conversely, the number of unique ISs, the diver-
sity index, and the VCN were generally higher in lymphoid cells,
in agreement with the selective growth advantage effect of gene-
corrected clones belonging to this lineage. In addition, the lower
number of ISs and the lower diversity of BM- versus PB-derived
myeloid progenitor and mature cells might reflect the effect of
sampling from a localized tissue site versus the PB, which should
more homogeneously represent overall output.
On the basis of these results, we studied IS similarities among
lineages purified from the first three WAS patients at the last BM
and PB collection to infer and test hematopoietic cell hierarchies
by combining conditional probability distributions and graphical
models of dependencies (Figure 4B; Supplemental Experi-
mental Procedures). In model 1, we assumed that the observa-
tion of a specific IS in a myeloid progenitor only conditions the
probability for the same IS to be observed in a mature myeloid
cell. These constraints were designed to recapitulate at best,
with our given set of data, a model where myeloid and lymphoid
cells are segregated early in the hematopoietic hierarchy and
should bemarked by a significantly distinct set of ISs. Inmodel 2,
we assumed that the observation of a specific IS in a myeloid
progenitor conditions the probability for the same IS to be
observed in both myeloid and lymphoid cells. This model was
designed to test the existence of a higher clonal relationship be-
tween myeloid and lymphoid cells as compared to model 1, due
to a late segregation of myeloid and lymphoid compartment
downstream of the hematopoietic hierarchy. Given these under-
lining structures, we tested our IS data collected from WAS
GT patients and measured which model best fit the observed
distribution of shared ISs along the lineages by means of the
Bayesian information criterion (BIC) (Supplemental Experimental
Procedures). As a result, the best-scoring model, based on IS
tracking data, was model 2, which suggests the existence of a
significant clonal relationship between myeloid and lymphoid
lineages, i.e., we found that the probability of detecting an IS
in a PB lymphoid lineage was significantly dependent on having
observed the same IS in a BM myeloid precursor.
We then added a dynamic component to the analysis of
clonal relationships, making use of sequence reads as surrogate
markers of clonal dimensions. This method is based on the
assumption that at time 0, transduced BM CD34+ cells re-
infused into patients have been unequivocally marked by IS co-
ordinates. Each individual cell fate is determined by a stochastic
sequence of events of three different types: duplication, death,
and differentiation into more committed cell types. Rates gov-
erning this dynamic evolution are assumed to be constant over
time, shared among cells belonging to the same lineage but
different across them. The result is that each cell behaves inde-
pendently, and the collections of observed clone dynamics
correspond to trajectories of the same underlying stochastic
process. On the basis of these assumptions, it is possible to
simultaneously impose branching structures and make infer-(B) Horizontal column graphs showing the real-time input of HSC or MPP shared
whole PB, BM MNCs, or PBMCs isolated from the same patient at the same tim
(C) Line plots showing the sharing scores (on y axis) of HSC orMPP ISs toward ind
Sharing scores were calculated according to the rules reported in Supplementalences about rates (Figure 4C, left schematic representation;
Supplemental Experimental Procedures).
In an exploratory setting, we only constrained the differentia-
tion process according to three levels of hierarchy, where we
assumed that BM CD34+ cells can differentiate into any other
cell type in the BM and PB, BM can be connected to any cell
type at the BM and PB level, and PB lineages cannot differen-
tiate. The output of the procedure was a matrix of rate estimates
(Supplemental Experimental Procedures) on which we per-
formed principal-component analysis (PCA) to calculate the
clonal proximity of different lineages (Figure 4C, right PCA
plot). In the resulting graph, the closer two or more lineages,
the higher their similarity based on estimated duplication, death,
and differentiation rates. In line with their differentiation potential
and in concordance with the long-term preservation of engrafted
progenitors, BM CD34+ cells (in green) were distinct from the
other lineages and displayed positive duplication-death rates
(Supplemental Experimental Procedures). Importantly, as ex-
pected from their different biological activity, the BM progenitors
and PB mature cells were clustered separately according to the
three estimated parameters of duplication, death, and differenti-
ation used as input for the PCA analysis. Another important vali-
dation of the analysis relied on the observation that the duplica-
tion-death rates were negative in all PB lineages (Supplemental
Experimental Procedures), confirming that these populations
require a clonal supply from the upstream progenitors. The bio-
logical consistency of these results allowed interrogating the
PCA analysis on more refined questions, as clustering PB popu-
lations according to similar population rates. Within the PB cells,
the algorithm clustered together lymphoid T and B cells, most
likely due to their common capacity of long-term survival and
clonal supply from shared lymphoid progenitors. Notably, these
estimates again revealed a proximity between NK and myeloid
cells, suggesting a parallelism in population rates that might
derive from a potential common origin of these two lineages.
This dynamic model also allowed the investigation of candi-
date branching structures to confirm the validity of those findings
obtained with the Bayesian approach, as shown in Figure 4B. To
achieve this, as reported in the Supplemental Experimental Pro-
cedures, we imposed a set of constraints to test which of the
models proposed in Figure 4B was more supported by the
experimental data. The results suggest again that the empirical
data appear to support a structure implying late branching of
myeloid and lymphoid lineages.
Assessment of Potential Unbalances in Clonal
Contribution due to Insertional Mutagenesis
The permanent molecular marking achieved by vector integra-
tion has the inherent potential to induce clonal skewing in vivo
due to insertional mutagenesis (Biasco et al., 2012). We thus as-
sessedwhethermajor clonal imbalances could be observed over
time in the PB of our patients, which might affect the interpreta-
tion of our IS data. As reported in Figure S3, none of the four GT-
treated patients showed overrepresented clones (composingISs as relative abundance (percentage of sequence counts) within whole BM,
e point.
ividual myeloid and lymphoid lineages over time (months after GT on the x axis).
Experimental Procedures.
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Figure 4. Hierarchical Relationships among Hematopoietic Lineages
(A) Dot plots representing, from left to right, the frequency of ISs shared with at least one other cell type, number of unique ISs, diversity index, and vector
copy number of different cell compartments isolated from four WAS patients at the last time point when both BM and PB were collected (Mann-Whitney U test:
*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001).
(B) Schematic representation of two alternative models of hematopoietic hierarchies implying distinct myeloid-lymphoid (left top graph) or myeloid-based (right
top graph) branching of hematopoietic differentiation. A Bayesian network approach was used to visualize, estimate, and compare complex dependence
structures among lineages of the first three WAS patients at last time point after GT (Supplemental Experimental Procedures) starting from IS data. The cor-
responding two different model constraints used for the test, not allowing or allowing probability dependencies between ISs retrieved in myeloid precursors and
(legend continued on next page)
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>20% of analyzed whole blood), and we could not detect any
evidence of IS-driven proto-oncogene perturbations leading to
clonal dominance up to 48 months after GT. Moreover, the pro-
file of genes neighboring vector ISs (Figure S4) was in line with
known LV insertional preferences and was still comparable
with that shown for the early follow-up of WAS GT patients (Aiuti
et al., 2013).
DISCUSSION
We herein described a detailed clonal tracking of hematopoietic
reconstitution dynamics and HSPC activity in humans at the
early and late stages after autologous transplantation. The num-
ber of tracked clones, homogeneously contributing to hemato-
poiesis in a highly polyclonal fashion, and the multiple cell types
analyzed permitted comprehensive and detailed observation of
the fate of human blood cells. Furthermore, as long-term moni-
toring using IS analyses, peripheral blood TCR Vbeta analyses,
multiple BM evaluations, karyotypic analyses, and clinical obser-
vation continues to show a lack of evidence for genotoxicity (Nal-
dini, 2015), we can consider LV genome marking to be mostly
neutral, thus providing a reliable tool for studying human hema-
topoiesis in vivo.
To address all the potential limitations of our analytical
methods, we used multiple approaches and stringent filtering
criteria. We exploited the statistical methodologies used in ecol-
ogy, which are specifically designed to account for sampling
variability. We also introduced customized data filtering to
reduce the confounding effects of sample impurity after sorting,
and we assessed and limited the impact of cross-contamination
during processing. To reinforce our results, we applied additional
filters and modeling constraints to account for PCR-related
biases affecting sequence reads and assessed the accuracy of
IS identification and quantification using dedicated validation as-
says (see Supplemental Experimental Procedures).
We analyzed several parameters at the individual lineage level
and unveiled the presence of two phases of human hematopoietic
reconstitution, and we provide an estimate of the number of en-
grafted clones actively contributing to long-term hematopoiesis
after transplantation.We showed that the reconstitution of human
hematopoiesis early after autologous transplantation is charac-
terized by fluctuating phases and that steady-state hematopoie-
sis is reached at 6–12 months. The clonal repertoire diversity
of each population in vivo was consistent with the longer time
needed to achieve lymphoid reconstitution and with the presence
of unevenly active clones in the initial reconstitution phases afterlymphoid mature cells, are schematically shown respectively on the left and right
using the Bayesian information criterion (BIC) score, which allows the statistica
shown above each panel. The resulting best-fitting model is framed with a red sq
(2010b). Differentiation potential are labeled as follows: E, erythroid; M, myeloid; B
CMP, commonmyeloid progenitor; CLP, common lymphoid progenitor; CMEP, co
MTP, myeloid-lymphoid T progenitor; and MBP, myeloid-lymphoid B progenitor
(C) Dynamic model of lineage similarities designed on m-dimensional continuou
representation and calculation formulas of different rates are shown on the left). P
and differentiation rates during the 12, 24 and 36 months after GT calculated on
components are shown on the PCA plot on the right.) Clustering of BM and PB
Similarities among lineages are shown by the relative distance or proximity of
Experimental Procedures).
See also Figures S3 and S4.GT.Our clonal population estimates revealed that only a few thou-
sand clones appear responsible for the maintenance of the whole
engineered blood system in steady state. In our GT trial, we
infused 80–230 million CD34+ HSPCs per patient (Aiuti et al.,
2013; Castiello et al., 2015). Considering that the gene-correction
frequency of infused CD34+ cells was above 88%, our estimates
suggest that about 1 in 105–106 gene-corrected HSPCs had the
potential to engraft long-term. Despite the fact that we could
not measure the actual number of infused HSCs and the potential
biases related to clones bearing more than one integrant, this es-
timate would fall in the upper range of our predictions, according
to themarking level of vector-positive CD34+ cells before infusion,
indicating that cell culture and transduction did not induce a sub-
stantial loss of harvested HSCs.
The estimated higher clonal abundance of BM CD34+ cells in
early versus steady-state phases of hematopoietic reconstitu-
tion might suggest that the first wave of short-term precursors
involves a larger population compared to that composed of
long-term engrafting HSPCs, which takes over hematopoiesis
only after 3–6 months. These results confirm and expand the in-
formation previously generated from clonal tracking in non-hu-
man HSPCs (Dykstra and Bystrykh, 2014; Gerrits et al., 2010;
Naik et al., 2013; Perie´ et al., 2014; Wu et al., 2014).
Unlike previous studies, our clonal tracking was performed
not only on PB mature populations but also on BM progenitors
purified at different time points, allowing real-time analysis of
progenitor output. Our data suggest that the first phases of he-
matopoietic reconstitution are most likely sustained by lineage-
committed progenitors that are possibly primed during in vitro
manipulation and are more numerous in the graft upon infusion.
We were able to identify a switch 6 months after GT when we
observed exhaustion of the first wave of clonal reconstitution,
reduction in the total number of CD34+ clones, and progressive
takeover of long-term HSCs, generating a stable output up to
the last follow-up 3 years after GT. There was little evidence of
lineage output from long-term HSCs during the first 6 months
post-GT, indicating a sharp segregation of tasks among the en-
grafting progenitors, with cells contributing to early hematopoietic
recovery being short-lived and mostly of restricted lineage po-
tency, and long-term multi-potent HSCs apparently entering
quiescence within this time. We considered that potential uneven
distribution of early engrafting clones in the BM niches might
affect the detection of HSCs active in early versus late phases.
However, the tracking of PB cells, and in particular of PB myeloid
populations (a recognized surrogate readout for progenitor activ-
ity), also confirmed the independent clustering of two distinctpanels. A measure of the strength of informativeness of each model is provided
l comparison of different hierarchical structures. The resulting BIC scores are
uare. Models of hematopoietic hierarchies are adapted from Kawamoto et al.
, lymphoid B; and T, lymphoid T. Common progenitors are labeled as follows:
mmonmyeloerythroid progenitor; CMLP, commonmyelolymphoid progenitor;
.
s-time stochastic Markov process, observed at fixed time points (schematic
rincipal-component analysis (PCA) performed on estimated death, duplication,
IS sharing and sequence reads belonging to each IS. (The first two principal
lineages is shown as rounded areas colored in blue and orange, respectively.
the boxes tagged with their relative cellular surface markers (Supplemental
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clonal waves in PB lineages that are, by definition, much less
affected by sampling biases than topologically localized BM
HSCs (Figure S2).
Our clonal characterization of bona fide HSCs and MPPs iso-
lated frompatients at 3 years after GT showed that at least a frac-
tion of BM-resident HSCs actively contributes to the hematopoi-
etic output in real time at the time of analysis (Figure 3B). The
relative fraction of HSC clones involved in hematopoietic pro-
duction was lower compared to MPPs (30% versus 80%), indi-
cating that a substantial proportion of HSCs is dormant for a pro-
longed time. Nonetheless, we achieved formal proof of the ability
of individual human HSC clones to constantly self-renew and
differentiate in vivo over a period of up to 3 years. The absolute
number of clones identifiable over time (15 versus 8) and the
extent of overall multilineage output (Figure 3C) were greater
for HSCs than for sampledMPPs. Intriguingly, these data appear
to partially differ from what was reported in a recent work, where
the authors suggest that native steady-state hematopoiesis
might be more actively supported by MPPs than by HSCs (Sun
et al., 2014). One remarkable result of our analysis was that
both progenitor subtypes isolated at steady-state hematopoie-
sis contained clones whose activity could be tracked back to
3–6 months after GT, but not earlier. Although obviously present
in the engrafted pool of HSPCs, these clones could not be iden-
tified as being active in the first months after GT. This suggests
that HSC clones were, for the most part, maintained quiescent
until the first active set of committed progenitors reached
exhaustion and potentially made space in the BM for the activa-
tion and expansion of long-term HSC clones and their differenti-
ation inside committed progenitor niches (Morrison and Scad-
den, 2014). In this context, one could postulate that the MPP
clones isolated at 3 years, and showing peripheral output well
before, had an HSC phenotype at previous time points. It is still
possible, however, that MPPs, contained in the infused sample
of transduced CD34+ cells, engrafted and preserved their
phenotype and might thus be endowed with long-term self-re-
newing potential like HSCs. Additional investigations are under-
way based on the prospective tracking of different subsets of
human HSPCs.
Our results on IS-based tracking were consistent with the cur-
rent understanding of the biology of the hematopoietic system
and showed important parallelisms with data derived from the
tracking of normal hematopoiesis in animal studies. In particular,
our proposed model of human hematopoietic reconstitution is in
agreement with the nature of blood cell repopulation reported in
wild-type rhesus macaques after transplant with genetically
modified HSPCs (Kim et al., 2014). These similarities include
(1) the observed timing of exhaustion of the first wave of short-
term progenitors, (2) the stable contribution of multipotent pro-
genitors with a balanced myelolymphoid potential at steady
state, and (3) the estimated relative small fraction of stem cell
clones actually contributing to the long-term clonal output. Our
findings constitute a comparative platform to test the validity of
animal studies in recapitulating human hematopoiesis and could
be of significant help on refining and reducing the use of animals
in future preclinical xeno-transplantation studies.
Importantly, these observations strongly suggest that
although clonal tracking studies in humans can be conducted,
by definition, only in the context of clinical trials based on the ge-116 Cell Stem Cell 19, 107–119, July 7, 2016netic correction of a diseased background, hematopoiesis in our
WASGT patients was, for themost part, restoredwith physiolog-
ical reconstitution dynamics to normal levels. Indeed, hemato-
logical and clinical parameters of the patients (including BM
and PB cell counts, immune phenotype, morphology, and karyo-
type as well as the number of CD34+ progenitor cells), with the
exception of platelet counts, are all comparable to those of
healthy untreated age-matched individuals (unpublished data).
Given the initial lymphopenic environment and the fludarabine
conditioning, the dynamics of lymphoid reconstitution observed
in the peripheral blood of WAS patients during the early phases
after GT could partially differ from other allogeneic HSPC trans-
plantation settings (Alho et al., 2016; Moratto et al., 2011; Pai
et al., 2006; Shin et al., 2012). Importantly, in WAS patients
showing normalization of lymphocytes content after allogeneic
HSPC transplantation, T cell counts reached a plateau at
12months after transplant (Pai et al., 2006), a result in agreement
with our data on lymphocyte recovery dynamics. It will be also
important, in future studies, to compare the pattern of reconsti-
tution in our patients with those observed in other GT trials using
myeloablative conditioning and in disease contexts where no se-
lective advantage for gene-corrected lymphocytes is expected
(Biffi et al., 2013; Cartier et al., 2009). Still, the nature of hemato-
poietic reconstitution in WAS patients does not suggest that
there is an original defect in the progenitor niches of the lymphoid
compartment. Actually, most of the selective advantages for
gene-corrected lymphocytes occur at later stages of maturation,
indicating that, upon correction of the genetic defect, the nor-
mally engrafting progenitors became able to fully overcome the
cell-intrinsic differentiation defect (Aiuti et al., 2013; Castiello
et al., 2015).
As all patients reached a normal and stable hematopoietic
output at 12 months after GT, we reasoned that this clinical
setting represents a valid model to interrogate steady-state
blood cell production in humans. With the application of
model-driven statistical approaches, we showed that the proba-
bility of observing an IS in amature lymphoid cell was statistically
dependent on observing the same IS in a myeloid progenitor
(Figure 4B; Supplemental Experimental Procedures). These
data support the recently proposed myeloid-based model of he-
matopoiesis, envisaging the existence of common myelolym-
phoid progenitors distinct from the HSC (Kawamoto et al.,
2010b). The dynamic framework developed for this study, em-
ploying individual clonal sizes to estimate death, duplication,
and differentiation rates, was coherent with the accepted biology
of the hematopoietic system and allowed unsupervised clus-
tering of BM and PB lineages. Within the BM compartment,
CD3+ and CD14+ cells were distinct from the other BM Lin+ cells.
This might be due to the fact that some or most of these cells re-
circulated from other sites to the BM at the time of collection,
therefore being genealogically distinct from the locally sampled
BM precursors. With regard to PB cell types, both our statistical
model and the unsupervised clustering of clonal relationships
with CD34+ cells shown in Figure 2C support the notion that
NK CD56+ cells might have a distinct origin compared to other
lymphoid cells and are possibly more closely related to the
myeloid lineage. These results match the observations recently
made in non-human-primate clonal tracking studies, on the ba-
sis of which Wu et al. propose an ontologically distinct origin of
NK cells (Wu et al., 2014), and are in accordance with Grzywacz
et al. model, in which human NK cells are able to differentiate
from myeloid progenitors (Grzywacz et al., 2014). Overall, we
believe that the statistical and mathematical models developed
for this study represent valid instruments to investigate complex
biological processes, such as the shape of hematopoietic differ-
entiation in vivo in humans using IS analysis. Future refinement of
these tools might increase the resolution and precision of the
assessment of clonal relationship and behavior.
No progressive clonal expansion was detected in any of the
studied patients, and we can reasonably assume that the pro-
portion and impact of clones representing >5%of the population
on our analysis of clonal dynamics is negligible (7 putative over-
represented clones out of 89,594 tracked clones, or 0.008% of
the analyzed population; Figure S3). These data strongly suggest
that our tracking system was not substantially affected by vec-
tor-related aberrant clonal skewing.
We herein provide a comprehensive clonal tracking of he-
matopoietic reconstitution after HSPC transplantation in hu-
mans. The information collected in our study validates some
long-standing models regarding human hematopoiesis and
sheds light on the clonal dynamics of blood cells in vivo at early
and late stages, as well as on HSPC activity in steady-state he-
matopoiesis in humans. In addition, our results further establish
the potential of the safe and extensive engineering of human he-
matopoiesis with ex vivo LV gene transfer. These data provide a
crucial reference for the follow-up of ongoing HSPC GT clinical
trials and will be critical in designing novel approaches for the
treatment of a wide spectrum of hematological disorders.
EXPERIMENTAL PROCEDURES
Patients
Four male WAS patients (age range, 1.1–5.9 years) for whom no human leuko-
cyte antigen (HLA)-identical sibling donor or suitable matched unrelated donor
was available, underwent LV GT at amedian age of 2.75 years after a reduced-
conditioning regimen protocol (Aiuti et al., 2013; Castiello et al., 2015; Cicalese
and Aiuti, 2015) (http://www.clinicaltrials.gov, #NCT01515462). CD34+ cells
were isolated from the BM of all patients (for patient 1, a proportion of
CD34+ cells were also isolated from granulocyte colony-stimulating factor
[G-CSF] mobilized PB), transduced ex vivo with the LV w1.6W vector, and re-
infused at a similar dose ranging from 8.9 to 14.1 CD34+ cells/kg. Clinical pro-
tocol, CD34+ transduction conditions, methods to calculate transduction effi-
ciency, VCN of infused cells, andmeasurement of clinical endpoints have been
reported elsewhere (Aiuti et al., 2013). All patients treated with LV GT in this
study are alive and clinically well at the time of submission of this report. Pa-
tients recovered from transient neutropenia following chemotherapy, showed
gradual reduction in the frequency and severity of infection and bleeding, and
became independent from platelet transfusion. No clinical manifestations of
autoimmunity were observed after year 1 of follow-up, and no adverse event
associated with vector integration has been reported to date (unpublished
data). Biological samples were obtained fromWAS patients, with the approval
of the San Raffaele Scientific Institute’s ethics committee, together with con-
sent from patients or parents.
Collection of Samples for IS Analysis
CD3+, CD4+, CD8+, CD14+, CD15+, CD19+, and CD56+ cells were purified from
mononuclear cells (MNCs) from PB. CD3+, CD14+, CD15+, CD19+, CD34+,
CD56+, CD61+, and glycophorin+ (GLYCO) cells were purified from BM-
derived MNCs using positive selection with immunomagnetic beads (average
purity, 94.2%) according to themanufacturer’s specifications (Miltenyi Biotec).
Whole PB, peripheral blood mononuclear cells (PBMCs), whole BM, and BM
MNCs were also collected. A CFC assay was performed on ex vivo BMCD34+ cells according to the manufacturer’s specifications in Methocult
medium (STEMCELL Technologies). At day 14, colonies were collected and
genomic DNA was extracted for IS retrieval. Bone marrow MNC from WAS-
GT patients were isolated using Ficoll-Hypaque gradient separation (Lympho-
prep, Fresenius), and enriched for CD34+ cells with the human anti-CD34
MicroBeads Isolation Kit (Miltenyi Biotec) according to the manufacturer’s
specifications. To isolate HSCs and MPPs, CD34+ cells were labeled
with anti-human Lin cocktail (anti-CD3/CD14/CD16/CD19/CD20/CD56), anti-
CD15/CD34/CD38/CD45RA (BioLegend), and anti-CD90 (BD Biosciences)
fluorescent antibodies and FACS purified with the MoFlo-XDP cell sorter
(Beckman Coulter), achieving purity ranging between 92% and 99%. In total,
we collected 3,150 HSCs and 2,300 MPPs from patient 2 and 600 HSCs and
155 MPPs from patient 3 (see Supplemental Experimental Procedures).
IS Retrieval
ISs were collected from bead-isolated or FACS-sorted blood cell types
through LAM-PCR and high-throughput sequencing as previously described
(Aiuti et al., 2013). Genomic DNA from isolated cell types was extracted
(QIAamp DNA Blood Mini kit or Micro kit, QIAGEN), and whole-genome ampli-
fication was performed (Repli-G Mini Kit, QIAGEN) only on FACS-sorted HSC
and MPP populations as previously described (Biasco et al., 2015). Raw IS
datasets underwent a series of different filtering procedures, according to
the type of analysis required (see Supplemental Experimental Procedures).
Analysis of ISs for Clonal Tracking
The methods, as well as the mathematical and statistical tools used for all an-
alyses, are described in detail in Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.stem.2016.04.016.
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